ARA-290 (Cibinetide) | Pen

ARA-290 (Cibinetide) is a peptide positioned for controlled research settings where tissue-protective EPOR–CD131 signaling is being studied in relation to neuroinflammatory load, small-fiber integrity, and stress-induced cellular survival endpoints.

Supports

1. Innate repair receptor–linked cytoprotection (model-dependent)
2. Neuroinflammation-resolution signaling balance (marker-based)
3. Small-fiber structure and regeneration endpoints (e.g., corneal/skin measures)
4. Cell-survival pathway activation under injury stress (JAK/STAT, PI3K/Akt)
5. Ischemia-/inflammation-associated tissue resilience readouts (preclinical)

Description

ARA290 (cibinetide) is a synthetic peptide engineered from erythropoietin (EPO) structure-function research to preferentially engage tissue-protective signaling without the erythropoietic profile associated with full-length EPO. In mechanistic terms, it is commonly described as an agonist of the heteromeric receptor complex formed by the erythropoietin receptor (EPOR) and the β-common receptor (CD131), sometimes referred to as the “innate repair receptor” in the literature.

Across experimental systems, this receptor engagement is studied for its association with anti-inflammatory modulation and cytoprotective signaling programs that can be upregulated during cellular stress. Human and preclinical investigations have explored endpoints in small-fiber neuropathy contexts (including corneal and intraepidermal nerve metrics), alongside broader tissue-injury and inflammatory models where preservation of structure/function and inflammatory marker shifts are assessed.

ARA290 is positioned for laboratory research only, where study designs typically focus on quantifiable biomarkers, functional readouts, and histologic/structural endpoints relevant to injury response and repair-oriented signaling.

Clinical Status

Evaluated in human clinical research programs (including randomized controlled designs) for small-fiber neuropathy-related endpoints and tissue-protective biology, with additional supporting preclinical and in vitro evidence describing receptor biology and downstream signaling.

Evidence type:
Human RCT ✔ | Observational ✔ | Animal ✔ | In vitro ✔ | Regulatory approval ☐

Mechanism of Action

ARA290 is studied as a selective activator of EPOR–CD131 heteromer signaling, a receptor configuration associated with tissue-protective responses in non-hematopoietic cells. This contrasts with EPOR homodimer signaling that primarily mediates erythropoiesis, supporting the research rationale that certain EPO-derived peptides may separate cytoprotection from red-blood-cell stimulation.

Downstream, EPOR–CD131 engagement has been linked to activation of canonical survival and stress-response pathways such as JAK2/STAT signaling and PI3K/Akt-associated pro-survival programs, alongside modulation of inflammatory signaling networks. In experimental models, these pathway shifts are commonly measured via cytokine patterns, immune-cell activation states, barrier/tissue integrity markers, and structural recovery endpoints in injured tissues.

Benefits

• Selective activation of the innate repair receptor without hematopoietic stimulation:
  ARA 290 is derived from the helix-B surface of erythropoietin but lacks the structural configuration required to activate the homodimeric EPOR complex responsible for erythropoiesis. Instead, it binds to the heteromeric EPOR-CD131 receptor complex known as the innate repair receptor (IRR). This receptor configuration is expressed in non-hematopoietic tissues and becomes upregulated during cellular stress. By selectively engaging this receptor, ARA 290 activates protective signaling without increasing red blood cell production. This separation of cytoprotection from erythropoiesis is central to its mechanistic identity.
• Engages JAK2/STAT3-mediated cytoprotective signaling:
  Upon binding to the IRR complex, ARA 290 activates Janus kinase 2 (JAK2), which subsequently phosphorylates STAT transcription factors. STAT3 activation promotes expression of genes involved in cellular survival and inflammatory resolution. This signaling cascade contributes to regulation of stress-response genes rather than proliferative hematopoietic pathways. The selective activation of JAK2/STAT3 within non-erythroid tissues underpins its cytoprotective profile.
• Activates PI3K/Akt pathways supporting cellular survival:
  ARA 290 stimulation of the innate repair receptor also initiates PI3K/Akt signaling. Akt phosphorylation promotes cell survival by inhibiting pro-apoptotic pathways and supporting mitochondrial stability. This pathway is particularly relevant in tissues exposed to metabolic or inflammatory stress. By enhancing Akt-mediated survival signals, ARA 290 contributes to preservation of cellular integrity in experimental injury models.
• Modulates pro-inflammatory cytokine signaling networks:
  Inflammatory stress often involves upregulation of cytokines such as TNF-alpha, IL-1beta, and IL-6. Activation of the innate repair receptor has been associated with modulation of these pro-inflammatory mediators. Rather than suppressing immune function broadly, ARA 290 appears to support resolution-phase signaling, helping shift cellular responses from inflammatory amplification toward repair-oriented pathways. This immune modulation profile differentiates it from systemic immunosuppressants.
• Supports neuronal resilience and nerve repair research:
  Neural tissues are particularly vulnerable to inflammatory and oxidative stress. The EPOR-CD131 complex is expressed in neuronal and glial cells during injury conditions. Activation of cytoprotective pathways in these cells supports investigation into nerve fiber preservation and functional recovery. ARA 290 has therefore been examined in models of small fiber neuropathy and neural injury to explore restoration of nerve integrity markers.
• Facilitates resolution of tissue stress responses:
  During tissue injury, cells activate protective pathways designed to limit damage and restore homeostasis. The innate repair receptor is part of this endogenous defense system. By selectively activating this receptor complex, ARA 290 amplifies natural protective signaling cascades. This positions it within regenerative biology research frameworks focused on enhancing intrinsic repair responses rather than forcing proliferative growth.
• Distinct from anabolic or endocrine growth peptides:
  Unlike growth hormone secretagogues or IGF-based peptides, ARA 290 does not stimulate systemic anabolic hormone cascades. Its activity is confined to stress-induced receptor complexes expressed in injured tissues. This localized signaling focus makes it mechanistically distinct from peptides designed to enhance muscle growth or metabolic rate. Its biological role centers on protection and stabilization rather than growth acceleration.
• Integrates vascular and endothelial protective signaling:
  The EPOR-CD131 receptor complex is also expressed in endothelial cells during inflammatory or ischemic stress. Activation of PI3K/Akt and STAT pathways in these cells may influence vascular stability and barrier function in experimental models. This expands the relevance of ARA 290 beyond neural tissue into broader cytoprotective biology research domains.
• Operates within endogenous innate repair systems:
  The innate repair receptor system is activated naturally in response to tissue injury. ARA 290 mimics a specific domain of erythropoietin that engages this protective pathway without activating erythropoiesis. By leveraging an existing endogenous mechanism, it enables study of how intrinsic repair biology can be amplified in controlled experimental contexts.
• Supports investigation into inflammation-resolution balance:
  Effective tissue recovery depends on timely transition from inflammatory signaling to resolution and repair. ARA 290 is studied for its role in facilitating this transition. By modulating cytokine expression and promoting survival pathways, it contributes to research examining how cells shift from damage response to structural stabilization.
  

Research Data

Stack Suggestions

ARA-290 is commonly combined with other neuroprotective and regenerative peptides to create comprehensive recovery protocols:

ARA-290 + BPC-157 – This combination addresses nerve regeneration (ARA-290) and broader tissue repair (BPC-157). BPC-157’s angiogenic effects may enhance nutrient delivery to regenerating nerves, while ARA-290’s selective neuroprotection targets nerve-specific pathways. Research models suggest synergistic effects on recovery timelines following peripheral nerve or spinal cord injuries.

ARA-290 + TB-500 – TB-500 (Thymosin Beta-4) contributes cell migration and extracellular matrix remodeling, complementing ARA-290’s direct neuronal protection. In models of traumatic nerve injury, this stack has been observed to accelerate both structural (axonal regrowth) and functional (sensory/motor) recovery. The mechanistic rationale involves TB-500 facilitating Schwann cell migration while ARA-290 activates their myelination programs.

ARA-290 + NAD+ – Neuronal energy metabolism is critical for regeneration. NAD+ supplementation supports mitochondrial function and ATP production, while ARA-290 provides anti-inflammatory and survival signaling. This combination may be particularly relevant in metabolic neuropathy models (diabetic, chemotherapy-induced) where energy deficits compound nerve damage. Both agents have been studied independently for neuroprotection with different but complementary mechanisms.

Caution: Stacks discussed are for experimental protocol design in research settings. They do not constitute safety or efficacy guidance for human therapeutic use. Always consider potential interactions and monitor appropriate biomarkers when combining research compounds.

Possible Side Effects

Human and preclinical publications commonly describe tolerability monitoring, but side-effect profiles can be study-, population-, and protocol-dependent. In research settings, cautious handling is advised, with attention to unexpected sensitivity reactions and any unanticipated changes in measured safety markers within the study design. This product is positioned for controlled research use only.

Scientific References

• ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Promotes Repair via the Innate Repair Receptor — Review/Translational
• Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain — Human RCT
• ARA 290 for Treatment of Small Fiber Neuropathy in Sarcoidosis: Clinical Outcomes and Nerve Fiber Endpoints — Human Observational/Clinical
• ARA290, a Non-Erythropoietic EPO Derivative, Attenuates Renal Ischemia/Reperfusion Injury — Animal
• Cibinetide Dampens Innate Immune Cell Functions and Modulates Inflammation in Experimental Colitis — In vitro/Animal
• ARA 290 Produces Long-Term Relief of Neuropathic Pain Coupled with Suppression of the Spinal Microglia Response — Animal
• Targeting the Innate Repair Receptor to Treat Neuropathy — Review
• Erythropoietin and Its Derivatives: From Tissue Protection to Immune Modulation — Review
• EPO Derivative ARA290 Attenuates Early Renal Allograft Injury in Rats — Animal
• A Phase 2 Clinical Trial on the Use of Cibinetide for Diabetic Macular Edema — Human Trial

Cautions

• For educational and scientific context only; not intended to diagnose, treat, cure, or prevent any disease.
• If you are pregnant, nursing, have a medical condition, or use prescription medication, consult a qualified professional.
• Discontinue use if sensitivity occurs.